G1 Therapeutics, Inc.
Символ: GTHX
NASDAQ
4.44
USDРыночная цена сегодня
-7.4160
Коэффициент P/E
-0.3307
PEG Ratio
232.23M
Капитал MRK
- 0.00%
Доходность DIV
G1 Therapeutics, Inc. (GTHX) финансовые отчеты
Балансовый отчет
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 345.99 | 82.2 | 145.1 | 221.2 | ||||||||||
balance-sheet.row.short-term-investments | 185.28 | 49.9 | 50.5 | 0 | ||||||||||
balance-sheet.row.net-receivables | 46.78 | 12.7 | 11.1 | 5.7 | ||||||||||
balance-sheet.row.inventory | 54.08 | 12.4 | 16.2 | 3.5 | ||||||||||
balance-sheet.row.other-current-assets | 30.42 | 7.6 | 7.1 | 13.2 | ||||||||||
balance-sheet.row.total-current-assets | 477.33 | 114.9 | 179.5 | 243.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 26.32 | 6.4 | 8 | 9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0.62 | 0.2 | 0.3 | 0.3 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.28 | 0 | 0.3 | 1.2 | ||||||||||
balance-sheet.row.total-non-current-assets | 27.23 | 6.6 | 8.5 | 10.5 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 504.55 | 121.5 | 188 | 254.1 | ||||||||||
balance-sheet.row.account-payables | 22.2 | 4 | 7.4 | 2.9 | ||||||||||
balance-sheet.row.short-term-debt | 31.9 | 1.3 | 1.1 | 1.1 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 116.16 | 51.6 | 82.6 | 81.9 | ||||||||||
Deferred Revenue Non Current | 2 | 0.5 | 1 | 1 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -46.6 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 73.94 | 23.8 | 27 | 23.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 210.97 | 56.4 | 83.6 | 82.9 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 18.01 | 4.3 | 6.8 | 7.9 | ||||||||||
balance-sheet.row.total-liab | 340.86 | 86.2 | 119.2 | 110.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -3090.2 | -780 | -732 | -584.5 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 2441.74 | 815.4 | 800.8 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -307.57 | 121.5 | 188 | -473.9 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -307.57 | - | - | - | ||||||||||
Total Investments | 185.47 | 50.1 | 50.5 | 0.3 | ||||||||||
balance-sheet.row.total-debt | 127.72 | 57.2 | 83.8 | 83.1 | ||||||||||
balance-sheet.row.net-debt | -74.71 | 24.9 | -10.8 | -138.1 |
Отчет о движении денежных средств
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -30.59 | -48 | -147.6 | -148.4 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0.5 | 0.5 | 0.5 | 0.5 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 1.2 | 0 | 0.6 | ||||||||||
cash-flows.row.stock-based-compensation | 10.67 | 14.5 | 20.6 | 22.3 | ||||||||||
cash-flows.row.change-in-working-capital | 1.14 | -5.2 | -5.3 | -8.8 | ||||||||||
cash-flows.row.account-receivables | 4.37 | -1.6 | -5.4 | -5.5 | ||||||||||
cash-flows.row.inventory | 3 | 3.7 | -12.7 | -3.5 | ||||||||||
cash-flows.row.account-payables | -0.37 | -3.4 | 4.4 | -0.7 | ||||||||||
cash-flows.row.other-working-capital | -4.26 | -4 | 8.4 | 0.8 | ||||||||||
cash-flows.row.other-non-cash-items | 9.12 | -1.4 | 3.1 | 1.7 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -18.18 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 50 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -116.81 | -124.7 | -65 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 122 | 127.5 | 15 | 0 | ||||||||||
cash-flows.row.other-investing-activites | -0.1 | 0 | -50 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 5.19 | 2.8 | -50.5 | 0 | ||||||||||
cash-flows.row.debt-repayment | -26.69 | -26.7 | 0 | -53.6 | ||||||||||
cash-flows.row.common-stock-issued | -0.01 | -0.2 | 52.4 | 86.4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -8.76 | -0.3 | 0.1 | 113.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -35.42 | -26.9 | 52.5 | 145.9 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -48.41 | -62.4 | -126.7 | 13.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 161.52 | 32.3 | 94.9 | 221.6 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 209.93 | 94.7 | 221.6 | 207.8 | ||||||||||
cash-flows.row.operating-cash-flow | -18.18 | -38.3 | -128.6 | -132.1 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | -18.18 | -38.3 | -129.1 | -132.1 |
Строка отчета о прибылях и убытках
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 84.04 | 82.5 | 51.3 | 31.5 | ||||||||||
income-statement-row.row.cost-of-revenue | 6.82 | 7.2 | 3.7 | 2 | ||||||||||
income-statement-row.row.gross-profit | 77.23 | 75.3 | 47.6 | 29.5 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 35.55 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.operating-expenses | 102.6 | 114.8 | 183.7 | 171.9 | ||||||||||
income-statement-row.row.cost-and-expenses | 106.34 | 122 | 187.5 | 173.9 | ||||||||||
income-statement-row.row.interest-income | 2.04 | 2.5 | 0.7 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.total-operating-expenses | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0.51 | 0.5 | 1.3 | -0.3 | ||||||||||
income-statement-row.row.ebitda-caps | -21.23 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -22.83 | -39.5 | -136.2 | -142.5 | ||||||||||
income-statement-row.row.income-before-tax | -27.48 | -44.9 | -145.9 | -147.4 | ||||||||||
income-statement-row.row.income-tax-expense | 3.12 | 3.1 | 1.7 | 0.9 | ||||||||||
income-statement-row.row.net-income | -30.59 | -48 | -147.6 | -148.4 |
Часто задаваемые вопросы
Что такое G1 Therapeutics, Inc. (GTHX) общие активы?
G1 Therapeutics, Inc. (GTHX) общие активы - 121540000.000.
Какова годовая выручка предприятия?
Годовая выручка - 29349000.000.
Какова норма прибыли компании?
Норма прибыли компании - 0.919.
Что такое свободный денежный поток компании?
Свободный денежный поток - -0.356.
Что такое норма чистой прибыли предприятия?
Норма чистой прибыли - -0.364.
Что такое общий доход компании?
Общая выручка - -0.272.
Что такое G1 Therapeutics, Inc. (GTHX) чистая прибыль (чистый доход)?
Чистая прибыль (чистый доход) - -47967000.000.
Что такое общий долг компании?
Общий долг - 57173000.000.
Что такое операционные расходы?
Операционные расходы - 114843000.000.
Какова цифра денежных средств компании?
Денежные средства предприятия - 19887000.000.